Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 1,270,000 shares, a growth of 58.9% from the December 15th total of 799,400 shares. Currently, 7.4% of the company’s shares are short sold. Based on an average daily trading volume, of 171,900 shares, the short-interest ratio is presently 7.4 days.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Barclays PLC raised its position in Telomir Pharmaceuticals by 325.1% in the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock worth $45,000 after purchasing an additional 5,367 shares during the period. Beaird Harris Wealth Management LLC grew its holdings in shares of Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock worth $70,000 after purchasing an additional 9,950 shares during the last quarter. State Street Corp increased its stake in Telomir Pharmaceuticals by 99.1% in the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after buying an additional 17,967 shares during the period. Bank of New York Mellon Corp purchased a new stake in Telomir Pharmaceuticals in the 2nd quarter valued at about $241,000. Finally, Suncoast Equity Management grew its stake in Telomir Pharmaceuticals by 109.9% in the 3rd quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after acquiring an additional 26,803 shares in the last quarter.

Telomir Pharmaceuticals Stock Down 1.1 %

TELO traded down $0.06 during trading on Thursday, reaching $4.79. The company had a trading volume of 64,370 shares, compared to its average volume of 123,466. Telomir Pharmaceuticals has a 52 week low of $3.11 and a 52 week high of $20.72. The business has a 50 day simple moving average of $4.59 and a 200-day simple moving average of $4.75.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.